AbbVie will no longer offer voluntary 340B pricing on any of its orphan-designated drugs to covered entities subject to such exclusions.

AbbVie, AstraZeneca Challenge Kansas’ New Contract Pharmacy Access Law

July 5, 2024 Shannon Young, Associate Editor/Senior Writer Views

Two major drug manufacturers this week sued Kansas in an effort to block the state’s new contract pharmacy access law, [...]

Please Login or Become a Paid Subscriber to View this Content

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!